3.0.0 5133 2023-01-11T13:44:05Z 2023-01-11T13:44:05Z House HR 2019-11-18 116 [Congressional Record Volume 165, Number 184 (Monday, November 18, 2019)][House]From the Congressional Record Online through the Government Publishing Office [www.gpo.gov]By Mr. CICILLINE:H.R. 5133.Congress has the power to enact this legislation pursuantto the following:Article 1, Section 8.[Page H8958]]]> hsju00 Judiciary Committee House Standing hsju05 Administrative State, Regulatory Reform, and Antitrust Subcommittee Discharged from 2019-11-19T15:48:09Z Referred to 2019-11-18T15:47:50Z Reported by 2020-12-24T15:32:58Z Markup by 2019-11-21T21:16:05Z Referred to 2019-11-18T17:01:25Z H. Rept. 116-695 116 1416 S 2019-06-28 Placed on Senate Legislative Calendar under General Orders. Calendar No. 132. Related bill CRS 116 2486 HR 2020-07-23 Message on House action received in Senate and at desk: House amendments to Senate amendment. Related bill CRS 116 4398 HR 2019-10-02 Referred to the Subcommittee on Antitrust, Commercial, and Administrative Law. Related bill CRS 2020-12-24 Placed on the Union Calendar, Calendar No. 578. Calendars H12410 2 House floor actions U00578 2020-12-24 Reported by the Committee on Judiciary. H. Rept. 116-695. Committee H12200 2 House floor actions hsju00 Judiciary Committee 2020-12-24 Reported by the Committee on Judiciary. H. Rept. 116-695. Committee 5000 9 Library of Congress hsju00 Judiciary Committee 2019-11-21 hsju00 Judiciary Committee 1 House committee actions Ordered to be Reported. Committee 2019-11-21 hsju00 Judiciary Committee 1 House committee actions Committee Consideration and Mark-up Session Held. Committee 2019-11-19 hsju00 Judiciary Committee 1 House committee actions Subcommittee on Antitrust, Commercial, and Administrative Law Discharged. Committee 2019-11-18 Referred to the House Committee on the Judiciary. IntroReferral H11100 2 House floor actions hsju00 Judiciary Committee 2019-11-18 hsju05 Administrative State, Regulatory Reform, and Antitrust Subcommittee 1 House committee actions Referred to the Subcommittee on Antitrust, Commercial, and Administrative Law. Committee 2019-11-18 Introduced in House IntroReferral Intro-H 9 Library of Congress 2019-11-18 Introduced in House IntroReferral 1000 9 Library of Congress C001084 Rep. Cicilline, David N. [D-RI-1] David Cicilline D RI N. 1 N C001093 Rep. Collins, Doug [R-GA-9] Doug Collins R GA 9 2019-11-18 True N000002 Rep. Nadler, Jerrold [D-NY-10] JERROLD NADLER D NY 10 2019-11-18 True S000244 Rep. Sensenbrenner, F. James, Jr. [R-WI-5] F. SENSENBRENNER R WI JAMES 5 2019-11-18 True M001208 Rep. McBath, Lucy [D-GA-6] Lucy McBath D GA 6 2019-11-20 False C001118 Rep. Cline, Ben [R-VA-6] Ben Cline R VA 6 2019-11-20 False Commerce Administrative remedies Civil actions and liability Competition and antitrust Consumer affairs Drug safety, medical device, and laboratory regulation Federal Trade Commission (FTC) Health care costs and insurance Inflation and prices Intellectual property Judicial review and appeals Manufacturing Prescription drugs Commerce

00 2019-11-18 Introduced in House 2020-12-31T17:04:47Z Affordable Prescriptions for Patients Through Promoting Competition Act of 2019

This bill prohibits, subject to certain exceptions, the practice of product hopping, which is presumed when a drug manufacturer obtains removal of a drug from the Food and Drug Administration's approved drug list, discontinues a drug, or markets a reformulation of an already approved drug during a certain period after which the manufacturer has been notified that a competing drug manufacturer has applied for generic drug approval.

]]>

07 2020-12-24 Reported to House 2020-12-31T17:30:58Z Affordable Prescriptions for Patients Through Promoting Competition Act of 2019

This bill prohibits, subject to certain exceptions, the practice of product hopping, which is presumed when a drug manufacturer obtains removal of a drug from the Food and Drug Administration's approved drug list, discontinues a drug, or markets a reformulation of an already approved drug during a certain period after which the manufacturer has been notified that a competing drug manufacturer has applied for generic drug approval.

]]>

Display Title Official Title as Introduced Reported in House RH Short Title(s) as Introduced Introduced in House IH Short Title(s) as Reported to House H House Reported in House RH Reported in House 2020-12-24T05:00:00Z https://www.govinfo.gov/content/pkg/BILLS-116hr5133rh/xml/BILLS-116hr5133rh.xml Introduced in House 2019-11-18T05:00:00Z https://www.govinfo.gov/content/pkg/BILLS-116hr5133ih/xml/BILLS-116hr5133ih.xml 2020-12-24 Placed on the Union Calendar, Calendar No. 578. text/xml EN Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain. Congressional Research Service, Library of Congress This file contains bill summaries and statuses for federal legislation. A bill summary describes the most significant provisions of a piece of legislation and details the effects the legislative text may have on current law and federal programs. Bill summaries are authored by the Congressional Research Service (CRS) of the Library of Congress. As stated in Public Law 91-510 (2 USC 166 (d)(6)), one of the duties of CRS is "to prepare summaries and digests of bills and resolutions of a public general nature introduced in the Senate or House of Representatives". For more information, refer to the User Guide that accompanies this file.